Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612675 | 0.98 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL22024919 | 0.98 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL20980158 | 0.98 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18923249 | 0.98 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18468195 | 0.98 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL21191655 | 0.97 | LMNA (0.41) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18745361 | 0.97 | LMNA (0.41) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18557089 | 0.95 | LMNA (0.40) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL21788784 | 0.95 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL22023897 | 0.92 | LMNA (0.40) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-04-21 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | SMN1; SMN2 2918/4885L3MBTL1 3199/4885LMNA 2443/4885 |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | MAVS, VRK1, VRK2 | SMN1; SMN2 2918/4885L3MBTL1 3199/4885LMNA 2443/4885 |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | SMN1; SMN2 4764/4885L3MBTL1 3336/4885LMNA 1030/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | SMN1; SMN2 4789/4885L3MBTL1 4081/4885LMNA 1554/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | SMN1; SMN2 4669/4885L3MBTL1 4720/4885LMNA 2656/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | SMN1; SMN2 4669/4885L3MBTL1 4720/4885LMNA 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.